Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.
about
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future stepsJC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of InfectionProgressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.Persistence and pathogenesis of the neurotropic polyomavirus JCImmunological Markers for PML Prediction in MS Patients Treated with NatalizumabCRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC InfectionExpanded CD8 T-cell sharing between periphery and CNS in multiple sclerosis.Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.Intercellular adhesion molecule-1 mediates murine colon adenocarcinoma invasion.Transient combination therapy targeting the immune synapse abrogates T cell responses and prolongs allograft survival in mice.Novel surgical techniques, regenerative medicine, tissue engineering and innovative immunosuppression in kidney transplantation.Central nervous system immune reconstitution inflammatory syndrome.Immune surveillance and response to JC virus infection and PML.Update on progressive multifocal leukoencephalopathy.The human JC polyomavirus (JCPyV): virological background and clinical implications.Biologic agents in islet transplantation.Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.Selectins and their ligands as potential immunotherapeutic targets in neurological diseases.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.Immune reconstitution inflammatory syndrome associated with biologic therapy.Targeting leukocyte trafficking for the treatment of inflammatory bowel disease.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.Frontline Science: CXCR7 mediates CD14(+)CD16(+) monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS.Memory T cells in organ transplantation: progress and challenges.Unintended Immunological Consequences of Biologic Therapy.Immunotargeting in the management of psoriasis.VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium.β2 Integrins As Regulators of Dendritic Cell, Monocyte, and Macrophage Function.ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphatNatalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.LFA-1 in T Cell Migration and Differentiation.
P2860
Q26823444-55EB6B10-5349-4A33-A3D0-29A75609C03BQ28552120-CE9926DC-5678-4BD4-BFA4-9DF2B499701DQ30235523-B49F8733-2FAD-408F-AFEE-6473B59154A6Q30699740-09B63D11-76B7-41BC-BD96-D61BA5DD671BQ34263719-C8603897-C737-4A63-819D-AF496FB31132Q34459843-6AC79472-2664-41E7-92E6-2F527BF68F9DQ34818048-284C6472-416D-46E1-A222-C30D1E3BEDB5Q35770584-F02A938C-47BC-4472-820F-CFCBC093B3CDQ35777258-FAC4DD02-5906-4251-92CF-F3A44D35BA4AQ36484399-1C1FAA1D-4052-4B3C-ACF0-C690E22DF5DEQ36834266-812DB993-A048-4823-B750-501386429811Q37042924-0524BB7C-B522-4F2D-81BB-D3E8AAC002D9Q37243068-C075C0BB-E50F-42AF-9B1D-D38BC0711D52Q37442512-ABE194D6-0C9E-4E2C-B433-0F80E2551A4CQ37678580-A88B7450-8D36-4FD8-B7F0-61B7419F989BQ38044681-2F89BFBE-C7FB-435A-B637-EEFC7765CDB3Q38115572-56CE5433-0FB3-4479-AC70-6604965ED406Q38126884-187C37E2-A44D-4CB1-9E9A-2EC6FB7BF4AFQ38141840-35DFDC4F-C1F7-4DF1-B882-6765CFF677CCQ38159803-22CABCAE-E011-441D-949C-4B3729ED5FBEQ38172961-EAA31AAA-358D-4A8D-A82D-157147030236Q38202636-511AC9BA-D9A5-4638-8190-97CAF7CC48A8Q38261176-115D0950-5AE9-47A8-AB9C-6C3FA415EF61Q38287572-22C25084-8162-4978-ADE6-CD8CCF3755DCQ38351464-ED176A30-9F79-44C7-A35B-E23A701207F0Q38534132-954E2DDB-ADD4-4A14-8AED-0437F061AF1EQ38650120-9558D3B9-FE07-4D75-A0E5-5A48F9627021Q38654347-28E23848-185F-4B2A-9986-3F0C679D3DBEQ38753494-99A0C31D-227E-4AB3-9666-8A273F58C5F8Q38871098-2847F850-FA2F-4E3A-83EB-78AC7F9F624CQ38912240-A2D59FA3-37EA-4E9B-8077-675852577C08Q41966039-3CA24917-80D5-48DE-9E0F-C2EA99234EF3Q47688274-C47F4FB0-8A42-4500-A253-9210B2A777BCQ49357688-E411AEC5-6CFA-4FD2-98F9-2F89186645B3Q50086043-31DE60E4-C76E-49D7-83EF-484DED9FD299Q50871306-85FCE382-3488-4540-A7DA-1A0720AEB4E5Q54207309-20DAA8C4-2EEC-452D-AE8A-041E8966E814
P2860
Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Fatal PML associated with efal ...... grin αLβ2 in JC virus control.
@ast
Fatal PML associated with efal ...... grin αLβ2 in JC virus control.
@en
type
label
Fatal PML associated with efal ...... grin αLβ2 in JC virus control.
@ast
Fatal PML associated with efal ...... grin αLβ2 in JC virus control.
@en
prefLabel
Fatal PML associated with efal ...... grin αLβ2 in JC virus control.
@ast
Fatal PML associated with efal ...... grin αLβ2 in JC virus control.
@en
P2093
P2860
P1433
P1476
Fatal PML associated with efal ...... grin αLβ2 in JC virus control.
@en
P2093
B C Kieseier
C M Monoranu
J C Ulzheimer
R A Du Pasquier
R M Ransohoff
S M Staugaitis
P2860
P304
458-67; discussion 465
P356
10.1212/WNL.0B013E3182478D4B
P407
P50
P577
2012-02-01T00:00:00Z